Close
  Indian J Med Microbiol
 

Figure 2: HPLC chromatogram for qualitative analysis of the metabolite profiles in the plasma of rats treated with cimifugin, Prime-Oglucosylcimifugin (PGCN), and 4-O-β-D-glucosyl-5-O-methylvisamminol (GML). (a)Blank plasma samples. (bd)blank plasma added with reference standards of cimifugin, PGCN, andGML, respectively. (e)Blank plasma added mixtures of the reference standards of three chromes derivatives. (f(1)f(3))Plasma samples from a rat 0.5, 1, and 5 h after oral administration of cimifugin, respectively. (g(1)g(3))plasma samples from a rat 0.5, 1, and 5 h after oral administration of PGCN, respectively.(h(1)h(3)) Plasma samples from a rat 0.5, 1, and 5 h after oral administration of GML, respectively

Figure 2: HPLC chromatogram for qualitative analysis of the metabolite profiles in the plasma of rats treated with cimifugin, Prime-Oglucosylcimifugin (PGCN), and 4-O-β-D-glucosyl-5-O-methylvisamminol (GML). (a)Blank plasma samples. (bd)blank plasma added with reference standards of cimifugin, PGCN, andGML, respectively. (e)Blank plasma added mixtures of the reference standards of three chromes derivatives. (f(1)f(3))Plasma samples from a rat 0.5, 1, and 5 h after oral administration of cimifugin, respectively. (g(1)g(3))plasma samples from a rat 0.5, 1, and 5 h after oral administration of PGCN, respectively.(h(1)h(3)) Plasma samples from a rat 0.5, 1, and 5 h after oral administration of GML, respectively